RxDoctor Payments Data

Marissa Patterson, APRN

Family · Edmond, OKNPI 1043883036

Payments from drug & device makers

$2,770in general payments, 2019–2025

Across 145 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$384
  • Lilly USA, LLC$355
  • Pfizer$277
  • Boehringer Ingelheim$273
  • Novo Nordisk$251
  • Abbott$183
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,770 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$14,965
Medicare patients
81
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$43,171
OzempicSemaglutide28$30,519
JardianceEmpagliflozin29$28,466
Spiriva RespimatTiotropium Bromide19$10,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,426
EliquisApixaban13$7,663
Albuterol Sulfate HfaAlbuterol Sulfate53$1,331
Atorvastatin Calcium70$830
Azelastine Hcl15$738
Duloxetine Hcl21$709
Omeprazole28$551
Ezetimibe18$506
Pantoprazole Sodium18$497
Losartan Potassium38$447
Bupropion XlBupropion Hcl17$414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$355$43,17135 claims
Boehringer IngelheimJardiance, Spiriva Respimat$273$38,92048 claims
Novo NordiskOzempic$251$30,51928 claims
GSKTrelegy Ellipta$44$8,42613 claims
PfizerEliquis$277$7,66313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →